EXPLORA BIOLABS

Oncology Services

Explora BioLabs is a San Diego-based contract research organization (CRO) that provides preclinical *in vivo* contract research services to the biotech, pharmaceutical and academic communities. Explora is managed by scientists, for scientists. In-depth scientific knowledge, reliable experimental skills and excellent customer service are our strengths. We provide extensive preclinical research services in oncology.

Expertise in Preclinical Development

Explora's research team has:

- Sound knowledge of tumor biology
- Extensive experience in oncology drug development
- Excellent technical and surgical capability
- Established IACUC protocols

We can assist with:

- Model selection and study design
- *In vivo* drug screening
- Mechanistic studies
- Sophisticated data and statistical analyses
- General technical reports (GTR) generation for IND filing
- On-site technical support and training

Rodent Cancer Models

Explora has experience with numerous oncology animal models used to test anti-cancer therapies, including the following:

Subcutaneous xenograft models, which are usually human tumors or cell lines transplanted into immuno-compromised rodents.

- NCI-60 cancer cell lines (over 30 lines characterized in-house for tumorigenicity)
- Commercial or client-produced cell lines



Orthotopic tumor models, which are cells implanted directly into organs of interest.

- Mammary fat pat (mfp) model
- Renal capsule, spleen models
- Prostate, ovarian models
- Brain tumor model

Metastatic models, which are used for testing drugs that block metastases.

- Forced metastatic models
- Spontaneous metastatic models

Hu-SCID models, which are used with human immune system substitution in development of antibody therapy and immunotherapy.

- Human PBL grafts
- Human immune organ grafts
- Cord blood grafts

Syngeneic models, which are rodent tumors transplanted into hosts of the same genetic background to study immunotherapy and biological pathways.

- Melanoma B16
- Mammary TA3
- Lewis lung carcinoma

Assays and Endpoints

Explora can help you obtain high-quality, meaningful data from every study. Common assays and endpoints in oncology studies include:

- Tumor size reduction and remission
- Tumor growth delay
- Decrease in metastases
- Drug effects on host and tumor
- Increase in lifespan of the host
- Changes in biomarkers

Contact us to find out how Explora can help you contain costs, meet timelines, and achieve your preclinical research goals.

www.explorabiolabs.com Email: info@explorabiolabs.com Tel: 858-273-6574